Hypertension (HT) in young (< 40 years) is a significant problem in India. Preventing cardiovascular disease in these young hypertensives is a major challenge as management strategies for young hypertensives are not very clear. Risk assessment in young hypertensives is also limited as most of the risk assessment algorithms apply to population above 40 years. Unfortunately, we do not have a specific algorithm for Indian patients. The algorithm given by Joint British Societies (JBS-3) appears to be most suited for risk assessment in young Indian Hypertensive individuals. Additionally, multiple newer markers may be needed to understand the cardiovascular risk completely in the young hypertensive population.
INTRoDuCTIoN
Hypertension (HT) is the leading cause of cardiovascular (CV) morbidity and mortality all over the globe. The incidence of HT is rising rapidly in the Asian countries including India. Approximately 30% adults (> 20 years of age), urban as well as rural, are suffering from HT in India.
1,2 A focused approach is required to manage this alarming increase in the incidence of hypertension and allied risk factors. Since the morbidity and mortality in HT results from CV events, every hypertensive must undergo assessment of risk for CV events. Aggressive management of high risk patients lowers the elevated risk. Aggressive management strategy today includes antihypertensive drugs, therapeutic lifestyle changes (TLC), statins and aspirin. Since TLC may be good for every adult, the issue of risk assessment boils down to use of statins and aspirin in young hypertensives. Thus,
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the purpose of risk assessment is to identify individuals who will derive significant benefits from drug therapy.
Young Hypertensive
Although hypertension affects adult population (>18 years), most of the studies have included people over 50 years of age and limited data exists about younger people especially below 40 years of age. India is a young country with 65% of its population under 35 years of age. According to 2014 data, India has about 380 million individuals in the age group of 20 to 39 years. 3 Assuming a modest estimate of hypertension prevalence of 20% in this population, number of hypertensive individuals in this age group exceeds 75 million. This large number of hypertensive individuals if not detected and treated in time will exert tremendous burden on the healthcare systems in the years to come. Unfortunately, data about risk assessment and management of hypertension in this age group is sparse. Detection of hypertension in this group of young individuals is a challenge as most of them are asymptomatic. Even when hypertension is detected, physicians may be reluctant to label them with a medical diagnosis that may have implications for the future insurance, jobs and perceptions of health. 4 Besides, significance of isolated systolic hypertension (ISH) or isolated diastolic hypertension (IDH) at young age remains a matter of debate. However, recent data indicate that ISH even in young confers added CV risk. 5 Long-term follow-up data from Chicago Heart Association Detection Project in Industry study 6 showed that ISH in the young was associated with higher CV risk as compared to high normal blood pressure (BP) over follow-up of 31 years. Harvard Alumni Health study 7 also showed elevated BP in the early life (university entry) was associated with higher risk of all-cause mortality over follow-up of more than 40 years. Similar observations have been reported from follow-up of more than 4 decades in Glasgow University students. 
CARDIoVASCulAR RISk ASSeSSmeNT
Management of hypertension today focuses more on management of global CV risk in addition to of control hypertension. 9 Every hypertensive must be carefully evaluated for risk factor congregation and target organ damage at the baseline and during follow- 15 have found that the JBS-3 score provides more accurate estimation of CV risk in Indian subjects than ASCVD score. Thus for calculation of global CV risk in young Indian hypertensive population JBS-3 appears to be the best suited model in absence of one developed in India. The risk calculator is readily available online and using this can be very handy in assessing risk in clinical practice. Calculated risk above 20% is indicative of significant risk to qualify the patient for drug therapy for primary prevention.
As the morbidity and mortality attached to hypertension results from CV events secondary to atherosclerosis, assessment of subclinical damage may give important clues in individuals with hypertension. Risk calculators, however, do not consider markers of subclinical atherosclerosis/arteriosclerosis like hs-CRP (exception-Reynolds Score), Aortic Stiffness measured by pulse wave velocity (PWV), ankle-brachial index, carotid intima-media thickness (cIMT) and microalbuminuria. Due to limited data on integration of these markers of vascular health in global risk prediction, it is unclear how a clinician should use this knowledge. European society of cardiology recommends that subjects with evidence of subclinical atherosclerosis should be allocated to higher risk category than that calculated with SCORE. 16 An integrated approach to evaluation of CV risk is developed at Rasmussen Center for Cardiovascular disease prevention at the University of Minnesota, MN, 17 which involves 10 tests (Table 2) to generate a disease score (DS). Each test is scored as point 0 for normal, 1 for borderline abnormal and 2 for abnormal result. A disease score above 6 is considered high risk score and is related to higher occurrence of morbid CV events over 6 years follow-up.
Considerable data are accumulated about role of these added risk markers over past 2 decades. Estimation of these additional markers in young hypertensives can help in evaluating CV risk further especially for patients in intermediate risk category. In absence of large randomized data on addition of these markers to the classic risk scores, a clinician must use his clinical judgment in interpreting results of these tests on case to case basis. Current status of these markers is discussed briefly in the following section.
Abdominal obesity
Abdominal obesity is now recognized as an important contributor in development of diabetes and atherosclerosis especially in Asian Indians. Traditionally, obesity is 21 Simple inexpensive measurement of waist circumference in the young hypertensive patients can be used as a target thus helping in advising about weight reduction through regular exercise and diet modification.
Aortic Stiffness and Pulse Wave Velocity
Aortic stiffness is a marker of arterial stiffening (arteriosclerosis) and indicates arterial wall damage in the subclinical stage. 22 Measurement of carotid femoral pulse wave velocity (CFPWV) reflects stiffness of large arteries and is a strong predictor of future CV events. 23 Carotid femoral pulse wave velocity above 10 m/s is now considered abnormal according to the expert consensus statement of ESC (2012). Significant data indicate that use of CFPWV improves risk prediction in patients with hypertension without overt cardiovascular disease. [23] [24] [25] With measurement of CFPWV in the Framingham study, 26 15.7% of patients at intermediate risk could be reclassified into higher (14.3%) or lower (1.4%) risk. In another meta-analysis, 27 19 and 22% of the intermediate risk individuals were reclassified into higher or lower quartiles of risk. However, data on modulation of aortic stiffness and its impact on CV risk is limited 28 and will be evaluated in 4 years prospective Strategie de prevention Cardiovasculaire Basėe sur la Rigidité Arterielle (SPARTE) Study. Smaller studies indicate that ACE inhibitors, angiotensin receptor blockers and spironolactone reduce the aortic stiffness beyond their BP reducing effects while beta-blockers limit de-stiffening of arterial wall and in fact can increase it in some patient population.
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C-reactive Protein
High sensitivity C-reactive protein (hs-CRP) is an inflammatory biomarker which independently predicts future vascular events in diverse population ranging from healthy individuals 29, 30 to patients with acute coronary syndromes regardless of LDL cholesterol levels. Utility of elevated levels of hs-CRP over and above traditional risk factors in predicting 10 year CV events was clearly demonstrated in CV health study 31 which included men and women above 65 years of age without vascular disease. Data from JUPITER trial 32 shows that treatment of apparently healthy individuals above 50 years of age and elevated levels of hs-CRP (>2 mg/l) with rosuvastatin reduces major CV events significantly. Although utility of hs-CRP in younger individuals is not specifically demonstrated in a large randomized study, it should be equally powerful marker in this population too. The 2013 ACC/AHA guidelines 12 on the assessment of CV risk do not recommend use of this marker routinely in low risk individuals. However, it remains a very useful marker in people with intermediate risk (FRS 5 to 20%) to identify candidates for statin therapy (ACC/AHA IIb/B).
Carotid Intima-media Thickness
Imaging the carotid arteries provide a window to detect subclinical atherosclerosis by direct visualization of wall thickening measured as cIMT. 33 Elevated cIMT and/or presence of plaques in carotid arteries has been shown to predict occurrence of stroke and myocardial infarction independent of traditional risk factors. [34] [35] [36] [37] The relationship between cIMT and CV events is continuous and determining a threshold for CV events is rather arbitrary. Although, ESC guidelines 2007 considered cIMT >0.9 mm indicative of existing abnormality, threshold value for high CV risk was > 1.0 mm in the middle aged patients of European Lacidipine Atherosclerosis (ELSA) study. 38 In the atherosclerosis in the communities (ARIC) study 39 addition of cIMT and carotid plaques added little value for predicting CV events and reclassifying the patients into another risk category. Despite of these uncertainties a recent systematic review indicates added predictive value of cIMT in asymptomatic individuals at intermediate risk. 
Ankle-brachial Index (ABI)
Ratio of systolic BP measured at the ankle to brachia systolic BP provides useful assess ment of peripheral vasculature. Ankle-brachial index (ABI) < 0.9 indicates advanced peripheral vascular disease 41 and is related to 45, 46 Large population of young hypertensive patients in India demands early detection and optimal management to reduce subsequent morbidity and mortality. Unfortunately, strategies to optimally manage these young patients are lacking and we need to extrapolate the existing data about managing CV risk derived from older patient population. On one hand overestimation of CV risk in a young hypertensive can unnecessarily expose him to long-term drug therapy, on the other hand inadequate evaluation may lead to loss of opportunities of preventing CV events. Ideally, we need to develop specific strategies for this large pool of young hypertensive patients by systematic follow-up. Till such data are available, one can use the existing risk calcu lators (like JBS-3) as an initial tool to identify high risk group 
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